Navigation Links
Amicus Therapeutics Presents Positive Results From Phase 1 Clinical,Studies of Plicera for Gaucher Disease

Phase 2 Clinical Trials Initiated

CRANBURY, N.J., March 21, 2007 /PRNewswire/ -- Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, announced today that it will present positive results from its recently completed Phase 1 clinical studies of Plicera(TM) (isofagomine tartrate, AT2101) for Gaucher disease at the of Medical Genetics (ACMG) Annual Meeting on March 21-25 in Nashville, TN. The Phase 1 results show that Plicera was well-tolerated and that oral administration resulted in a significant elevation of target enzyme levels in healthy volunteers. Based on these results, Amicus announced today the initiation of two Phase 2 clinical trials of Plicera for Gaucher disease.

Plicera is designed to selectively bind to and stabilize GCase, the enzyme deficient in Gaucher disease. This deficiency leads to lysosomal accumulation of glucocerebroside inside certain cells, which is believed to cause the various symptoms of Gaucher disease. Plicera facilitates proper trafficking of the enzyme to the lysosomes, the compartments in the cell where it is needed to break down glucocerebroside.

Phase 1 Plicera data being presented at ACMG

Two double-blind, placebo-controlled, dose escalation Phase 1 studies in healthy volunteers were completed. These studies were designed to evaluate the safety, tolerability and pharmacokinetics of Plicera. In the first study, 36 subjects received a single dose of one of five dose levels of Plicera. The second study was a multiple-dose study in which 18 subjects received one of three dose levels of Plicera once daily for 7 consecutive days. In both studies, Plicera was safe and well tolerated at all doses. There were no serious adverse events and no subjects withdrew or discontinued due to an adverse event. In the multiple-dose study, a dose-depend
'"/>




Page: 1 2 3

Related medicine technology :

1. Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease
2. Amicus Therapeutics Presents Data From Preclinical and Phase 1 Studies of Amigal for Fabry Disease
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:9/30/2014)... 30, 2014   Easy Breathe , the fastest ... announced that it now offers the revolutionary AirSense ... the first sleep apnea therapy devices with internal cellular ... to track and share real-time data on each user,s ... CPAP therapy.  In addition, the internal modem allows the ...
(Date:9/30/2014)... ORANGE , N.J. and NEW BRUNSWICK, N.J., Sept. 30, ... affiliation agreement that allows Kessler Foundation and New ... advance biomedical research, education and patient care programs ... president and chief executive officer of Kessler Foundation ... New Jersey Health Foundation. "The experience ...
(Date:9/30/2014)... , Sept. 30, 2014 The Eastern European ... established medical-device providers as well as new medical-device manufacturers ... while simultaneously looking at ways to reduce the cost ... distributors is one of the effective means to achieve ... distribution market in Eastern European and provides profiles of ...
Breaking Medicine Technology:Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3
(Date:9/30/2014)... New York, NY (PRWEB) September 30, 2014 ... and falling demand have hampered growth in the ... Popular diets have caused consumers to moderate their ... growing consumer preferences for premium varieties shrunk the ... bread products. Successful operators proactively responded by introducing ...
(Date:9/30/2014)... been awarded a three-year $1.7 million grant from ... new imaging technologies and data analysis techniques that ... of neurons in the brain interact to process ... the precise interactions between millions of nerve cells ... alterations in these interactions that may be responsible ...
(Date:9/30/2014)... September 30, 2014 The American ... to help diabetics curb their sweet tooth, but the ... this September, suggests that zero-calorie sweeteners may actually ... diabetes. , The Weizmann Institute of Science in ... artificial sweeteners to mice, the mice developed glucose intolerance. ...
(Date:9/30/2014)... 2014 Regenerative Medicine Solutions (RMS) is ... in Nashville, Tennessee. RMS welcomes the launch of an ... expansion of a new treatment center for the Lung ... Apnea Institute to Nashville, the hope is to bring ... both diagnosed and undiagnosed. With Nashville being a hub ...
(Date:9/30/2014)... 30, 2014 (HealthDay News) -- Medicare should cover low-dose ... risk for the disease, a coalition of more than ... which includes the Lung Cancer Alliance, the Society of ... Cancer Society and the American Society of Clinical Oncology, ... the U.S. Centers for Medicare & Medicaid Services (CMS). ...
Breaking Medicine News(10 mins):Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2
... Small Business Committee Leaders to Press for Affordable ... 24 In advance of tomorrow,s,Finance Committee hearing ... Kerry (D-Mass.) and Olympia J. Snowe (R-Maine), Chairman ... and Entrepreneurship,sent a letter to the leaders of ...
... from a Phase I/II clinical trial of a novel ... In 26 patients with advanced solid tumors, treatment with ... yielding plasma concentrations above the expected therapeutic threshold, says ... in Montreal, Canada. Thallion has produced and tested ...
... seven exceptionally talented and creative investigators in the early ... Health Science (NIEHS), part of the National Institutes of ... made under NIEHSs Outstanding New Environmental Sciences (ONES) program. ... of our efforts to help establish the careers of ...
... supports vitamins for respiratory health , , WEDNESDAY, Oct. 24 (HealthDay ... of drinks a day may help keep the doctor away, ... daily dose of alcohol helps the heart, this study suggests ... for smokers. , "This is the biggest study that,s ever ...
... Oct. 24 Thelen Reid Brown Raysman &,Steiner ... group has,successfully assisted long-time client The Doctors Company ... major provider of healthcare liability,insurance, for an aggregate ... share in cash. (Logo: http://www.newscom.com/cgi-bin/prnh/20071016/AQTU238LOGO ) ...
... trend, PHILADELPHIA, Oct. 24 Governor Edward ... Reduction of Error,Fund (Mcare) claims have dropped by ... result of reforms, more insurers are writing malpractice ... when it comes to medical malpractice,",Governor Rendell said ...
Cached Medicine News:Health News:Kerry, Snowe Push Finance Committee on Small Business Health Care 2Health News:Kerry, Snowe Push Finance Committee on Small Business Health Care 3Health News:Phase I pharmacokinetic study of ECO-4601, a novel bifunctional targeting agent 2Health News:NIEHS awards outstanding new environmental scientists 2Health News:Drink or Two a Day May Help Lungs 2Health News:Drink or Two a Day May Help Lungs 3Health News:Drink or Two a Day May Help Lungs 4Health News:Thelen Assists The Doctors Company in Acquisition of SCPIE Holdings Inc. 2Health News:Governor Rendell Says Mcare Claims and Costs Are 50 Percent Lower Than in 2003 2
The CK method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase activity in serum and plasma...
For the quantitative in vitro determination of Cholesterol in serum and plasma....
For the quantitative in vitro determination of Alanine Aminotransferase (ALT) in serum and plasma....
... introduces the Tag-It™ Cystic Fibrosis Kit, the ... genotyping. With validated performance criteria, this highly ... superior mutation coverage for carrier screening in ... in newborns. ,The Tag-It™ Cystic Fibrosis ...
Medicine Products: